Terms: = Lung cancer AND B2M, P61769, 567, ENSG00000166710 AND Treatment
61 results:
1. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary cancer.
Chinchilla-Tábora LM; Montero JC; Corchete LA; González-Morais I; Del Barco Morillo E; Olivares-Hernández A; Rodríguez González M; Sayagués JM; Ludeña MD
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396726
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R; Fujimoto D; Nozawa T; Sano A; Kitamura Y; Fukuoka J; Sato Y; Kijima T; Matsumoto H; Yokoyama T; Miura S; Hata A; Tamiya M; Taniguchi Y; Sugisaka J; Furuya N; Tanaka H; Yamamoto N; Koh Y; Akamatsu H
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38360040
[TBL] [Abstract] [Full Text] [Related]
3. Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in lung Adenocarcinoma Patients.
Incze E; Mangó K; Fekete F; Kiss ÁF; Póti Á; Harkó T; Moldvay J; Szüts D; Monostory K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686184
[TBL] [Abstract] [Full Text] [Related]
4. The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.
Huang D; Zhou C; Barnes G; Ma Y; Li S; Zhan L; Tang B
Cancer Med; 2023 Aug; 12(16):17403-17412. PubMed ID: 37587845
[TBL] [Abstract] [Full Text] [Related]
5. Preoperative serum bilirubin is an independent prognostic factor for curatively resected esophageal squamous cell carcinoma.
Huang X; Chen Y; Yang H; Wang R; Chen Z
BMC Cancer; 2023 Jul; 23(1):706. PubMed ID: 37507653
[TBL] [Abstract] [Full Text] [Related]
6. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
[TBL] [Abstract] [Full Text] [Related]
7. Safety and Efficacy of Immune Checkpoint Inhibitors in cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell lung cancer.
Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation.
Kuang M; Zhou Z; Lu Z; Shen W; Ge H; Tao X; Zhao Y; Zhuge L; Sun Y; Ji D; Zhang H
Clin Respir J; 2023 Mar; 17(3):148-156. PubMed ID: 36710485
[TBL] [Abstract] [Full Text] [Related]
9. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell lung cancer (NSCLC)-A Single Center, Retrospective Observational Study.
Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
[TBL] [Abstract] [Full Text] [Related]
10. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract] [Full Text] [Related]
11. Pathological Stage N1 Limited-Stage Small-Cell lung cancer Patients Can Benefit From Surgical Resection.
Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
Clin Lung Cancer; 2023 Jan; 24(1):e1-e8. PubMed ID: 36085281
[TBL] [Abstract] [Full Text] [Related]
12. Increasing Time-to-treatment for lung cancer: Are We Going Backward?
Muslim Z; Stroever S; Razi SS; Poulikidis K; Baig MZ; Connery CP; Bhora FY
Ann Thorac Surg; 2023 Jan; 115(1):192-199. PubMed ID: 35780818
[TBL] [Abstract] [Full Text] [Related]
13. Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models.
Žilionytė K; Bagdzevičiūtė U; Mlynska A; Urbštaitė E; Paberalė E; Dobrovolskienė N; Krasko JA; Pašukonienė V
Cancer Immunol Immunother; 2022 Nov; 71(11):2691-2700. PubMed ID: 35364740
[TBL] [Abstract] [Full Text] [Related]
14. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
Santini D; Zeppola T; Russano M; Citarella F; Anesi C; Buti S; Tucci M; Russo A; Sergi MC; Adamo V; Stucci LS; Bersanelli M; Mazzaschi G; Spagnolo F; Rastelli F; Giorgi FC; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; Grossi F; De Tursi M; Di Marino P; Pala L; Queirolo P; Bracarda S; Macrini S; Gori S; Inno A; Zoratto F; Tanda ET; Mallardo D; Vitale MG; Talbot T; Ascierto PA; Pinato DJ; Ficorella C; Porzio G; Cortellini A
J Transl Med; 2021 Jun; 19(1):270. PubMed ID: 34167578
[TBL] [Abstract] [Full Text] [Related]
15. b2m gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract] [Full Text] [Related]
16. Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells.
Han X; Chen L; Hu Z; Chen L; Sun P; Wang Y; Liu Y
J Proteomics; 2021 Apr; 237():104122. PubMed ID: 33561557
[TBL] [Abstract] [Full Text] [Related]
17. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract] [Full Text] [Related]
18. Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients.
Liao X; Cui Y; Chen X; Di L; Tong Z; Liu M; Wang R
Nucl Med Commun; 2020 Nov; 41(11):1210-1217. PubMed ID: 32815896
[TBL] [Abstract] [Full Text] [Related]
19. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic lung Adenocarcinoma With EGFR Mutations Receiving First-line treatment of Tyrosine Kinase Inhibitors.
Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL
Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632
[TBL] [Abstract] [Full Text] [Related]
[Next]
